Cargando…

Anti-TGF-β1 aptamer enhances therapeutic effect of tyrosine kinase inhibitor, gefitinib, on non-small cell lung cancer in xenograft model

Transforming growth factor β (TGF-β) is a multifunctional cytokine that plays crucial pathophysiological roles in various diseases, such as cancer and fibrosis. However, the disease modulation by targeting TGF-β1 isoform remains to be established, regardless of several studies employed with limited...

Descripción completa

Detalles Bibliográficos
Autores principales:	Takahashi, Masaki, Hashimoto, Yoshifumi, Nakamura, Yoshikazu
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Society of Gene & Cell Therapy 2022
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9481871/ https://www.ncbi.nlm.nih.gov/pubmed/36189081 http://dx.doi.org/10.1016/j.omtn.2022.06.001

Ejemplares similares

An Inducible TGF-β2-TGFβR Pathway Modulates the Sensitivity of HNSCC Cells to Tyrosine Kinase Inhibitors Targeting Dominant Receptor Tyrosine Kinases
por: Kleczko, Emily K., et al.
Publicado: (2015)

Photoprocesses of the tyrosine kinase inhibitor gefitinib: from femtoseconds to microseconds and from solution to cells
por: Tamarit, Lorena, et al.
Publicado: (2021)

Proliferation of Ewing sarcoma cell lines is suppressed by the receptor tyrosine kinase inhibitors gefitinib and vandetanib
por: Andersson, Mattias K, et al.
Publicado: (2008)

Metabolic Glycoengineering Sensitizes Drug-Resistant Pancreatic Cancer Cells to Tyrosine Kinase Inhibitors Erlotinib and Gefitinib
por: Mathew, Mohit P., et al.
Publicado: (2015)

Enhanced Expression of CD47 Is Associated With Off-Target Resistance to Tyrosine Kinase Inhibitor Gefitinib in NSCLC
por: Nigro, Annunziata, et al.
Publicado: (2020)

β‐Hydroxyisovalerylshikonin Is a Novel and Potent Inhibitor of Protein Tyrosine Kinases
por: Hashimoto, Sachiko, et al.
Publicado: (2002)

Significant increase in hEGF uptake is correlated with formation of EGFR dimers induced by the EGFR tyrosine kinase inhibitor gefitinib
por: He, Peng, et al.
Publicado: (2013)

Gefitinib, an EGFR Tyrosine Kinase inhibitor, Prevents Smoke-Mediated Ciliated Airway Epithelial Cell Loss and Promotes Their Recovery
por: Valencia-Gattas, Monica, et al.
Publicado: (2016)

Epithelial Transfer of the Tyrosine Kinase Inhibitors Erlotinib, Gefitinib, Afatinib, Crizotinib, Sorafenib, Sunitinib, and Dasatinib: Implications for Clinical Resistance
por: Honeywell, Richard J., et al.
Publicado: (2020)

Therapeutic Innovations: Tyrosine Kinase Inhibitors in Cancer
por: Dervisis, Nikolaos, et al.
Publicado: (2016)

Multiple Therapeutic Applications of RBM-007, an Anti-FGF2 Aptamer
por: Nakamura, Yoshikazu
Publicado: (2021)

Anti-tumor activity of the TGF-β receptor kinase inhibitor galunisertib (LY2157299 monohydrate) in patient-derived tumor xenografts
por: Maier, Armin, et al.
Publicado: (2015)

Aptamers: A Review of Their Chemical Properties and Modifications for Therapeutic Application
por: Adachi, Tatsuo, et al.
Publicado: (2019)

Single-round isolation of diverse RNA aptamers from a random sequence pool
por: Imashimizu, Masahiko, et al.
Publicado: (2018)

A high-content EMT screen identifies multiple receptor tyrosine kinase inhibitors with activity on TGFβ receptor
por: Lotz-Jenne, Carina, et al.
Publicado: (2016)

Targeting the receptor tyrosine kinase RET in combination with aromatase inhibitors in ER positive breast cancer xenografts
por: Andreucci, Elena, et al.
Publicado: (2016)

Targeting the degradation of AXL receptor tyrosine kinase to overcome resistance in gefitinib-resistant non-small cell lung cancer
por: Bae, Song Yi, et al.
Publicado: (2015)

Tyrosine Phosphoproteomics of Patient-Derived Xenografts Reveals Ephrin Type-B Receptor 4 Tyrosine Kinase as a Therapeutic Target in Pancreatic Cancer
por: Renuse, Santosh, et al.
Publicado: (2021)

Tyrosine kinase receptor B attenuates liver fibrosis by inhibiting TGF-β/SMAD signaling
por: Song, Yu, et al.
Publicado: (2023)

Establishment and characterization of patient-derived xenograft models of gastrointestinal stromal tumor resistant to standard tyrosine kinase inhibitors
por: Na, Young-Soon, et al.
Publicado: (2017)

Metformin attenuates gefitinib-induced exacerbation of pulmonary fibrosis by inhibition of TGF-β signaling pathway
por: Li, Li, et al.
Publicado: (2015)

TGF-β Inhibitors for Therapeutic Management of Kidney Fibrosis
por: Park, Cheol Ho, et al.
Publicado: (2022)

DS-1205b, a novel selective inhibitor of AXL kinase, blocks resistance to EGFR-tyrosine kinase inhibitors in a non-small cell lung cancer xenograft model
por: Jimbo, Takeshi, et al.
Publicado: (2019)

The Functional Crosstalk between HER2 Tyrosine Kinase and TGF-β Signaling in Breast Cancer Malignancy
por: Wang, Shizhen Emily
Publicado: (2011)

Neutralizing Aptamers from Whole-Cell SELEX Inhibit the RET Receptor Tyrosine Kinase
por: Cerchia, Laura, et al.
Publicado: (2005)

Cell Surface Labeling and Detection of Protein Tyrosine Kinase 7 via Covalent Aptamers
por: Albright, Savannah, et al.
Publicado: (2023)

Pazopanib, a Receptor Tyrosine Kinase Inhibitor, Suppresses Tumor Growth through Angiogenesis in Dedifferentiated Liposarcoma Xenograft Models()()()
por: Li, Haifu, et al.
Publicado: (2014)

Tyrosine Kinase Inhibitors and Interferon
por: Dimou, Maria, et al.
Publicado: (2014)

Tyrosine Kinase Inhibitors for the Elderly
por: Hohenforst-Schmidt, Wolfgang, et al.
Publicado: (2016)

Tyrosine Kinase Inhibitors and Pregnancy
por: Abruzzese, Elisabetta, et al.
Publicado: (2014)

Nanomedicine of tyrosine kinase inhibitors
por: Smidova, Veronika, et al.
Publicado: (2021)

Targeting c‐met receptor tyrosine kinase by the DNA aptamer SL1 as a potential novel therapeutic option for myeloma
por: Zhang, Yibin, et al.
Publicado: (2018)

Tyrosine Kinase Inhibitors Regulate OPG through Inhibition of PDGFRβ
por: O’Sullivan, Susannah, et al.
Publicado: (2016)

Modulation of β-Catenin Signaling by the Inhibitors of MAP Kinase, Tyrosine Kinase, and PI3-Kinase Pathways
por: Zhang, Wenwen, et al.
Publicado: (2013)

Small molecule tyrosine kinase inhibitors in pancreatic cancer
por: Gupta, Sachin, et al.
Publicado: (2008)

EGFR and MET receptor tyrosine kinase-altered microRNA expression induces tumorigenesis and gefitinib resistance in lung cancers
por: Garofalo, Michela, et al.
Publicado: (2011)

Hepatocyte growth factor reduces sensitivity to the epidermal growth factor receptor-tyrosine kinase inhibitor, gefitinib, in lung adenocarcinoma cells harboring wild-type EGFR
por: Yang, Hua, et al.
Publicado: (2016)

Clinical responses to EGFR-tyrosine kinase inhibitor retreatment in non-small cell lung cancer patients who benefited from prior effective gefitinib therapy: a retrospective analysis
por: Watanabe, Satoshi, et al.
Publicado: (2011)

Metabolism of the EGFR tyrosin kinase inhibitor gefitinib by cytochrome P450 1A1 enzyme in EGFR-wild type non small cell lung cancer cell lines
por: Alfieri, Roberta R, et al.
Publicado: (2011)

Mutations in the MET tyrosine kinase domain and resistance to tyrosine kinase inhibitors in non-small-cell lung cancer
por: Yao, Yu, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_9631707u6ulltam00ie099ahs9